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ABSTRACT
MicroRNAs (miRNAs) enable colonic epithelial cells to acquire malignant 
characteristics and metastatic capabilities. Recently, cancer relevant miRNAs 
deregulated during disease progression have also been identified in tumor-associated 
stroma.
By combining laser-microdissection (LMD) with high-throughput screening 
and high-sensitivity quantitation techniques, miRNA expression in colorectal cancer 
(CRC) specimens and paired normal colonic tissue was independently characterized 
in stromal and epithelial tissue compartments. Notably, deregulation of the key 
oncogene miR-21 was identified exclusively as a stromal phenomenon and miR-106a, 
an epithelial phenomenon in the malignant state.
MiRNAs identified in this study successfully distinguished CRC from normal 
tissue and metastatic from non-metastatic tumor specimens. Furthermore, in a 
separate cohort of 50 consecutive patients with CRC, stromal miR-21 and miR-556 
and epithelial miR-106a expression predicted short disease free survival (DFS) 
and overall survival (OS) in stage II disease: miR-21 (DFS: HR = 2.68, p = 0.015; 
OS: HR = 2.47, p = 0.029); miR-556 (DFS: HR = 2.60, p = 0.018); miR-106a (DFS:  
HR = 2.91, p = 0.008; OS: HR = 2.25, p = 0.049); combined (All High vs. All Low. DFS:  
HR = 5.83, p = 0.002; OS: HR = 4.13, p = 0.007).
These data support the notion that stromal as well as epithelial miRNAs play 
important roles during disease progression, and that mapping patterns of deregulated 
gene expression to the appropriate tumor strata may be a valuable aid to therapeutic 
decision making in CRC.
INTRODUCTION
The majority of deaths from CRC are not caused 
by primary tumors, which are often resectable, but by 
metastatic disease, to which the most troublesome and 
intractable symptoms can be attributed and to which most 
patients eventually succumb [1, 2]. Despite increasing 
use of metastectomy and chemotherapy over time, the 
proportion of patients with metastatic disease who survive 
beyond 2 years remains as low as 28% [3]. Without 
treatment median survival is 8 months [4], but the addition 
of chemotherapy and newer targeted therapies may 
enhance this figure to 12 and 16 months respectively [4, 5].
The emergence of targeted therapies has been made 
possible through a greater understanding of the molecular 
characteristics of CRC. Although the results of clinical 
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trials have been disappointing, extending survival by 
only a few months [6, 7], these studies offer proof-of-
principle that therapeutic strategies translated from a better 
understanding of the mechanisms of disease can be applied 
to CRC. Equally significant is the prospect that molecular 
profiling may lead to more personalized patient care as 
therapeutic approaches become increasingly tailored to 
individual patient’s needs [8].
Consequently, in recent times, the identification of 
biomarkers capable of predicting outcome or response 
to therapy and the identification of putative therapeutic 
molecular targets in CRC have become important 
priorities [9, 10].
MicroRNAs (miRNAs) are a class of highly 
conserved non-coding RNA molecules with essential 
regulatory and homeostatic cellular functions. They 
are deregulated in all cancers examined to date, and 
aberrant expression in CRC promotes both malignant 
transformation and metastatic progression [11–13]. 
Crucially, tumors of different developmental origin and 
tumors of progressive pathological stage exhibit unique 
patterns of deregulated miRNA expression, which has 
prompted extensive research to explore the potential 
clinical roles of miRNA profiling from whole tumor 
sections, lymph nodes, metastases, serum and even feces 
of patients with CRC [11, 14].
Emerging data suggests that metastasis relevant 
miRNAs are not simply confined to malignant 
epithelial cells but are also present in the stromal tissue 
surrounding a tumor. Deregulated stromal miRNAs may 
play an important role during metastatic progression by 
regulating the phenotype of cancer associated stromal 
cells [15–17] and through paracrine effects resulting from 
exosomal intracellular transfer [18, 19]. They may also 
provide valuable prognostic and diagnostic information 
during CRC progression as well as opportunities for 
novel pharmacological intervention [20, 21]. However, 
systematic studies characterizing discrete patterns of 
deregulated miRNA expression in CRC stroma and 
epithelium are lacking.
The purpose of the current study is to identify 
miRNAs deregulated in the CRC stroma and epithelium 
at different clinically relevant stages and to examine their 
clinical utility as biomarkers of disease progression.
RESULTS
Stromal and epithelial tissue compartments 
produce distinct patterns of miRNA deregulation 
in CRC
Most cancer research is focused on tumor cells; 
however recent developments suggest that molecular 
events in surrounding stromal cells may also play key 
roles during disease progression. To identify stromal 
miRNAs deregulated in CRC we conducted QuantimiR™ 
qPCR microarray analysis using RNA collected from 10 
patients (5 Duke’s A and 5 Duke’s C). LMD stroma from 
primary CRC tissue specimens frozen in liquid nitrogen 
at the time of surgery was compared with stroma from 
paired, uninvolved, proximal colonic tissue from the same 
patient.
In total, 5 miRNAs were significantly upregulated 
and 13 miRNAs significantly downregulated in CRC 
stroma compared with paired normal tissue (Figure 1A). 
Amongst the miRNA candidates upregulated more than 
X2-fold were miR-19a and -19b and miR-21, which are 
recognized oncogenes [22–26].
Subsequent profiling of LMD CRC epithelium 
from the same patient cohort revealed an entirely distinct 
pattern of miRNA deregulation compared with stromal 
tissue. In contrast to stroma, 13 epithelial miRNAs were 
significantly upregulated and 5 miRNAs significantly 
downregulated in CRC epithelium compared with paired 
normal colonic epithelium (Figure 1B). Except for miR-
19a and 19b, upregulated more than X2-fold in both CRC 
epithelium and associated stromal tissue, no other miRNA 
candidates were deregulated in both tumor strata.
These data emphasize the clear biological 
distinctions between stromal and epithelial tissue 
compartments, which may be masked if molecular 
analysis is not appropriately stratified.
Stromal miRNA expression profiles distinguish 
CRC tissue from paired normal colonic tissue
To validate our findings, we examined expression 
of the most highly deregulated stromal miRNAs by 
QuantimiR™ PCR profiling using the more sensitive and 
specific Taqman®qRT-PCR technique in all 10 paired CRC 
specimens. Mean expression of miR-21 and miR-19a was 
X4.0 and X2.1 fold greater in tumor stroma compared with 
paired normal stroma (p < 0.05). MiR-192 and miR-194 
were not significantly differentially expressed, however, a 
X3.3 fold reduction in miR-215 expression in tumor tissue 
did reach statistical significance (p < 0.05) (Figure 2).
These data suggest that deregulated stromal 
miRNAs may be capable of distinguishing CRC tissue 
from normal colonic tissue and support the notion that the 
response of the tumor microenvironment during malignant 
transformation is dynamic.
Stromal miRNA expression profiles distinguish 
metastatic from non-metastatic CRC specimens
To identify stromal miRNA candidates with specific 
relevance during CRC progression we reanalyzed our 
QuantimiR™ qPCR data to characterize differences in miRNA 
expression between the stroma of early stage (Duke’s A) 
(n = 5) and late stage (Duke’s C) (n = 5) CRC specimens.
Of the 95 miRNAs examined, 7 were found to 
be significantly differentially expressed by a factor > 2 
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between Duke’s A and Duke’s C tumors (Figure 3A). 
Taqman® validation confirmed that mean miR-214 
expression was increased X2.1 fold in Duke’s C specimens 
compared with Duke’s A (p < 0.05), whereas miR-192 and 
mir-194 expression were relatively suppressed by a factor 
of X4.1 and X3.6 respectively (p < 0.05) (Figure 3B).
The most highly suppressed stromal miRNAs in 
Duke’s C compared with Duke’s A tumors by QuantimiR™ 
(miR-200a and miR-215), were also shown to be 
suppressed by Taqman® qPCR, (p < 0.05) (Figure 3B).
These data, which identify distinct patterns of 
stromal miRNA expression in metastatic and non-
metastatic tumor groups, highlight the potential prognostic 
and diagnostic applications of stromal non-coding RNA 
molecules in CRC.
Robust miRNA profiles are extracted from 
formalin-fixed paraffin-embedded and fresh-
frozen CRC tissue archives
Next, we wanted to examine the utility of stromal 
miRNA expression profiling in a ‘real-world’ clinical 
scenario.
In the current study we used FFPE tissue, as 
most centers in the UK performing surgery for CRC 
preferentially use this method of tissue preservation. 
However, in terms of the quality and stability of RNA 
in long term storage, flash-freezing in liquid nitrogen 
has traditionally been considered a superior technique. 
Therefore to ensure our approach was adequate, 
QuantimiR™ qPCR miRNA microarrays were used to 
compare expression of 95 biologically relevant miRNAs 
in paired FFPE and fresh-frozen tissue in a representative 
number (n = 3) of CRC specimens selected at random 
from our archive (Figure 4A).
We found that miRNA expression correlated closely 
in CRC tissue preserved by the two techniques (R2=0.73–
0.89) (Figure 4A). These data support an increasing body 
of evidence which suggests that miRNAs are stable over 
time in archived FFPE tissue and that robust molecular 
profiles may be generated from CRC specimens fixed in 
formalin as well as fresh-frozen material. [27, 28]
Stromal and epithelial miRNAs predict patterns 
of tumor recurrence in stage II CRC
To examine the prognostic utility of stromal miRNA 
expression profiling in stage II (lymph node negative, 
metastasis negative) CRC, a database of patients was 
generated from our extensive archive of FFPE tumor 
tissue. Of this carefully matched group of patients with no 
histological or clinical features of biologically aggressive 
Figure 1:  MiRNAs significantly differentially expressed by a factor > 2 ( p < 0.05) in (A) CRC stroma vs. paired normal 
colonic stroma; and (B) CRC epithelium vs. paired normal colonic epithelium. QuantimiR™-qPCR analysis was performed 
using total RNA extracted from fresh-frozen LMD tissue from 10 patients with CRC.
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disease, half (n = 25) subsequently developed metastases 
within 5 years and half remained metastasis free (Table 1). 
Median follow-up for this cohort of 50 patients was 6.08 
years (95% CI: 4.98–7.19).
Each CRC specimen was subjected to LMD and 
total RNA was extracted separately from tumor stroma and 
epithelium. Expression of miRNA candidates identified 
previously (Figure 2), were subsequently examined by 
Taqman®qRT-PCR.
In stroma, mean miR-21 expression was X1.84-fold 
greater in stage II tumors from patients who developed 
metastatic recurrence (stage II-R) compared with patients 
who did not (stage II-NR) (p < 0.05) (Figure 4B). 
Stratifying patients into high and low expression groups 
relative to mean miR-21 expression for the group as a 
whole (mean = 0.857; 95% CI: 0.607–1.107) revealed that 
13 out of 25 patients with stage II-R disease expressed 
high levels of stromal miR-21 compared with 6 out of 25 
patients with stage II-NR disease (p < 0.05).
Patients expressing high levels of stromal miR-21 
had significantly shorter disease free survival (DFS) (HR 
= 2.68, 95% CI: 1.21–5.93, p = 0.015) (Figure 4D) and 
overall survival (OS) (HR = 2.47, 95% CI:1.19–5.55, 
p = 0.029) (Figure 6A) than patients expressing low 
levels of stromal miR-21. 13 out of 19 patients with high 
stromal miR-21 expression developed distant metastases 
during the period of follow-up compared with 12 out of 
31 patients in the low stromal miR-21 expression group 
(p < 0.05).
Stromal miR-214 and miR-215 were not 
significantly differentially expressed in recurrence and 
non-recurrence groups and so were not included in 
survival analysis (Figure 4B). However, we did want to 
examine whether panels of deregulated miRNA expression 
provided better prognostic discrimination than miRNA 
candidates examined in isolation, which prompted us to 
extend our analysis to epithelial miRNAs identified in our 
QuantimiR™ screen (Figure 1B).
Mean expression of miR-224, the most upregulated 
miRNA candidate identified in CRC epithelium, was not 
significantly different in LMD epithelium from stage 
II-R and stage II-NR tumor specimens (Figure 4C). 
However, mean expression of miR-106a, the second most 
deregulated epithelial miRNA was increased X1.88 fold 
in the LMD epithelium of stage II-R CRC specimens 
compared with stage II-NR specimens (p < 0.05) (Figure 
4C). When patients were stratified into high and low 
miR-106a expression groups (mean = 0.372; 95% CI: 
0.265–0.478), patients expressing high levels of epithelial 
miR-106a had significantly shorter DFS (HR = 2.91, 95% CI: 
Figure 2: Validation of stromal miRNA candidates deregulated in fresh-frozen CRC vs. paired normal colonic tissue 
by Taqman®qRT-PCR (*p < 0.05; **p < 0.005; NS= not significant).
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1.32–6.42, p = 0.008) (Figure 4E) and OS (HR = 2.25, 
95% CI: 1.00–5.04, p = 0.049) (Figure 6B) than patients 
expressing low levels of epithelial miR-106a. 13 out of 18 
patients with high epithelial miR-106a expression developed 
distant metastases during the period of follow-up compared 
with 12 out of 32 patients in the low epithelial miR-106a 
expression group (p < 0.05).
When considered in combination, high expression 
of stromal miR-21 and epithelial miR-106a were also 
associated with poor DFS (Both High vs. Both Low: HR 
= 5.09, 95% CI: 2.02–12.85, p = 0.001) (Figure 4F) and 
OS (Both High vs. Both Low: HR = 4.13, 95% CI: 1.48–
11.52, p = 0.007) (Figure 6D).
These data suggest that panels of deregulated 
miRNA expression from FFPE tissue, a widely available 
clinical resource, may provide practical prognostic 
information for clinicians treating patients with CRC.
MiRnome-wide miRNA profiling of laser 
microdissected tumor tissue reveals further 
promising prognostic bio-markers in CRC
Prompted by the successful combination of high-
throughput molecular screening and LMD, we broadened 
our approach to encompass miRnome-wide gene 
expression analysis.
From our cohort of 50 patients with stage II disease, 
10 stage II-R and 10 stage II-NR FFPE CRC specimens 
were selected at random (Table 2). Each was subjected 
to LMD and total-RNA was extracted separately from 
epithelial and stromal tumor strata. Global epithelial and 
stromal miRNA expression profiling was conducted using 
the 7th generation miRCURY LNA™ high-throughput 
screening platform.
In total, 95 miRNAs were significantly differentially 
expressed in stage II-R CRC stroma compared with stage 
II-NR stroma (Figure 5A), of which 10 were up- or 
down-regulated by a factor > 2 (p < 0.05). In contrast, 
63 epithelial miRNAs were significantly differentially 
expressed (Figure 5B); 6 by a factor > 2 (p < 0.05).
Subsequently we validated expression of our top 
scoring stromal candidate, miR-556, by conducting 
Taqman® qRT-PCR analysis in all 50 LMD tumor 
specimens. This confirmed mean miR-556 expression 
is increased X2.02-fold in the stroma of stage II CRC 
specimens which go on to metastasize compared with 
those which do not (p < 0.05) (Figure 5C).
When we stratified patients into high and low 
expression groups relative to mean expression (mean 
= 0.393; 95% CI: 0.266–0.519), those expressing high 
levels of stromal miR-556 had significantly shorter DFS 
(HR = 2.60, 95% CI: 1.18–5.73, p = 0.018) (Figure 5D), 
Figure 3: (A) Comparison of stromal miRNA expression in late stage (Duke’s C) vs. early stage (Duke’s A) CRC by 
QuantimiR™-qPCR. MiRNA candidates displayed are differentially expressed by a factor > 2 ( p < 0.05). (B) Validation of stromal 
miRNA candidates differentially expressed in late vs. early stage CRC by Taqman®qRT-PCR (*p < 0.05).
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but not significantly shorter OS (Figure 6C) than patients 
expressing low levels of stromal miR-556. 12 out of 17 
patients with high stromal miR-556 expression developed 
distant metastases during the period of follow-up 
compared with 13 out of 33 patients in the low stromal 
miR-556 expression group (p < 0.05).
When all three potentially prognostically relevant 
miRNA candidates identified in this study were 
considered in combination (stromal miR-21 and miR-
556; and epithelial miR-106a), we found that metastases 
developed in 7 out of 8 patients expressing high levels of 
all three candidates, compared with 12 out of 23 patients 
expressing high levels of two or one candidate; and 6 out 
of 19 patients expressing none of the candidates at high 
levels (p < 0.05). Furthermore, those expressing high 
levels of all three miRNAs had significantly shorter DFS 
(All High vs. All Low: HR = 5.83, 95% CI: 1.92–17.57; 
p = 0.002) (Figure 5E) (Patient characteristics may be 
found in Table 3).
DISCUSSION
Understanding the molecular events which underpin 
the metastatic cascade is important not only for the 
development of novel drugs, but also because categorizing 
heterogeneous tumors based on their molecular 
characteristics may lead to enhanced prognostication and 
better tailored treatment.
This is particularly relevant for patients with 
stage II CRC. Disease recurrence remains a substantial 
problem in this group as 20–25% of patients following 
surgery with curative intent go on to develop metastases 
within 5 years [1]. Although this clearly represents 
a significant minority of patients, the blanket use of 
Figure 4: (A) Correlation between the expression status of 95 cancer relevant miRNAs in fresh-frozen and FFPE tissue 
by QuantimiR™-qPCR, from 3 CRC specimens chosen at random from our archive. Expression of candidate stromal and 
epithelial miRNAs in stage II CRC specimens with (n = 25) and without (n = 25) disease recurrence at 5 years. Expression of (B) stromal 
and (C) epithelial miRNA candidates by Taqman®qPCR from total RNA extracted from FFPE LMD tissue. Stromal miR-21 expression 
and epithelial miR-106a expression were 1.84-fold and 1.88-fold greater respectively, in tumors which later metastasize compared with 
those which do not (*p < 0.05; NS = not significant). Kaplan-Meier curves of disease-free survival in patients with stage II disease based 
on significantly differentially expressed stromal and epithelial miRNAs. Patients were stratified into high or low expression groups based 
around group mean stromal miR-21 expression (D) or group mean epithelial miR-106a expression (E); or expression of stromal miR-21 
and epithelial miR-106a in combination (F) Stromal miR-214 and miR-215 and epithelial miR-224 were ubiquitously expressed between 
groups and were therefore not included in survival analysis (B and C).
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Table 1: Demographic data for all patients with stage II CRC with (stage II-R) and without 
(stage II-NR) metastasis at 5 years
Characteristics Stage II-R (n = 25) Stage II-NR (n = 25) p value
Age, years at diagnosis 
(mean+sd) 73.92 (11.45) 71.36 (11.57) 0.435
a
Gender (m:f) absolute numbers 21:4 17:8 0.321b
Tumour site 0.482b
Right Colon 6 9
Left Colon 11 12
Rectum 7 4
Stoma 1 0
Surgical setting 0.762c
Elective 18 16
Emergency 7 9
Histopathological data
Maximum tumour diameter (mm)
Mean (SD) 50.22 (26.00) 49.54 (18.70) 0.919
a
T stage 0.347b
T2 0 2
T3 18 16
T4 7 7
N stage
N0 25 25
M stage
M0 25 25
AJCC staging 7th ed 0.347b
Stage I 0 2
Stage IIA 18 16
Stage IIB 7 7
R0 resection margin 22 23 1.000c
Differentiation status 0.177b
Poor 2 2
Moderate-Poor 4 1
Moderate 7 14
Well-Moderate 12 8
Well 0 0
Extramural vascular invasion 4 1 0.349c
Tumour perforation 1 2 1.000c
Adjuvant therapy
(Continued )
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Characteristics Stage II-R (n = 25) Stage II-NR (n = 25) p value
Neoadjuvant Chemotherapy 3 2 1.000c
Neoadjuvant Radiotherapy 4 2 0.667c
Adjuvant Chemotherapy 6 2 0.247c
Adjuvant Radiotherapy 1 2 1.000c
Mean follow up, years (s.d) 2.89 (1.62) 5.40 (2.02) 0.000a
a = Independent t-test, b = Chi squared test, c = Fisher’s exact test
Table 2: Demographic data for patients selected at random from our archive to examine for 
array-based differential gene expression between stage II CRC with (stage II-R) and without 
(stage II-NR) recurrence at 5 years
Characteristics Stage II-R (n = 10) Stage II-NR (n = 10) p value
Age, years at diagnosis (mean+sd) 73.90 (11.31) 76.20 (8.43) 0.612a
Gender (m:f) absolute numbers 8:2 6:4 0.329b
Tumour site 0.132b
Right Colon 2 5
Left Colon 2 4
Rectum 5 1
Stoma 1 0
Surgical setting 0.370c
Elective 4 7
Emergency 6 3
Histopathological data
Maximum tumour diameter (mm)
Mean (SD) 50.50 (26.71) 49.50 (10.12) 0.913
a
T stage 0.171b
T2 0 2
T3 10 7
T4 0 1
N stage
N0 10 10
M stage
M0 10 10
AJCC staging 7th ed 0.171b
Stage I 0 2
Stage IIA 10 7
Stage IIB 0 1
(Continued )
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adjuvant treatment is not supported by evidence in this 
group [29]. Thus a molecular staging approach enabling 
early identification of patients at high risk of tumor 
recurrence would create the opportunity both to provide 
targeted interventions where necessary, and avoid 
overtreatment in other cases.
MiRNAs, which are non-coding RNA molecules 
with promising clinical applications, [30, 31] are well 
suited to this task. The analysis of miR-21 in plasma 
and stool [32–34] for example, has been identified as a 
potential diagnostic/screening tool in CRC and high miR-
21 expression in tumor [14] and serum [35] predicts poor 
post-operative outcomes.
MiRNAs also play significant roles during tumor 
initiation and progression, and an important theme in 
recent years is the emergence of pro-metastatic events in 
the tumor microenvironment regulated by miRNAs [16].
In the present study, miR-21 was the most highly 
upregulated stromal miRNA candidate in CRC tissue 
compared with paired ‘normal’ stroma by Taqman®qRT-
PCR. In a separate analysis of 50 patients with 
stage II CRC, stromal miR-21 was also significantly 
overexpressed in patients who developed metastases 
within 5 years compared with those that remained 
metastasis free.
MiR-21 is an important oncogene; antisense 
inhibition of miR-21 induces cellular apoptosis in 
cooperation with EGFR-tyrosine kinase inhibitors [36] and 
enhances sensitivity to radiotherapy and chemotherapy in 
a number of tumor contexts [37–39]. MiR-21 upregulation 
also enhances proliferation and invasion in pancreatic, 
glioblastoma and CRC cell lines [40–42]. However to 
date, all chemo-resistance and pro-metastatic mechanisms 
described have been limited to the malignant epithelium 
and yet observations from the current study contribute to 
a growing body of evidence which suggests deregulation 
of miR-21 is a stromal phenomenon in CRC, and not just 
a feature of cancer cells [15, 20, 43].
MiR-106a is also considered oncogenic in CRC. In 
contrast to miR-21, miR-106a was identified exclusively 
in LMD CRC epithelium in this study. MiR-106a is 
highly expressed in serum and primary malignant tissue 
of patients with CRC, [14, 44] and its presence in feces 
from tumor cell exfoliation into the gastrointestinal tract, 
has been identified as a potential adjuvant screening tool 
for colonic malignancies [45]. MiR-106a expression in 
CRC cell lines is also associated with enhanced invasion 
in vitro and in vivo and has been linked to known pro-
metastatic molecular pathways through direct translational 
suppression of transforming growth factorβ receptor 2 
(TGFBR2) [46].
Intriguingly, both miR-21 and miR-106a were 
identified in a previous study which compared miRNA 
expression in CRC and paired normal colonic tissue. 
However, in contrast to Schetter et al., [14] who used whole 
tumor tissue sections, we performed an initial LMD step prior 
Characteristics Stage II-R (n = 10) Stage II-NR (n = 10) p value
R0 resection margin 10 9 1.000c
Differentiation status 0.306b
Poor 0 1
Moderate-Poor 2 1
Moderate 3 6
Well-Moderate 5 2
Well 0 0
Extramural vascular invasion 1 0 1.000c
Tumour perforation 0 0
Adjuvant therapy
Neoadjuvant Chemotherapy 0 0
Neoadjuvant Radiotherapy 0 0
Adjuvant Chemotherapy 0 0
Adjuvant Radiotherapy 0 0
Mean follow up, years (s.d) 3.37 (1.41) 5.90 (2.23) 0.007a
a = Independent t-test, b = Chi squared test, c = Fisher’s exact test
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to profiling with high-throughput microarrays. Our approach, 
which was designed to avoid masking important biological 
differences between cancer cells and their supportive 
microenvironment, also allows us to map potentially relevant 
molecular events to the appropriate tumor compartment.
Crucially, we found that both elevated stromal 
miR-21 and epithelial miR-106a were associated with 
significantly reduced DFS and OS in patients with stage 
II CRC, which encouraged further interrogation of our 
QuantimiR™ screen:
MiR-215, miR-192 and miR-194 were each 
downregulated more than X2-fold in CRC stroma 
compared with paired ‘normal’ stroma, but only miR-215 
suppression was validated successfully by Taqman®.
Collective downregulation of all 3 miRNAs has 
previously been identified in nephroblastoma and is 
associated with upregulated activin receptor type 2B 
(ACVR2B) expression in the TGFβ pathway [47]. MiR-
192 and mir-215 are also positively regulated by the tumor 
suppressor p53 and are capable of inducing cell cycle arrest 
Figure 5: MiRnome-wide, high through-put miRNA screening: Heatmap of miRNAs differentially expressed (adjusted 
p < 0.05) in LMD stroma (A) and epithelium (B) between stage II CRC specimens with and without recurrence within 
5 years. (C) Taqman®qPCR validation reveals that miR-556 the most highly deregulated miRNA in our screen, is overexpressed x2.02-
fold in the stroma of stage II CRC specimens which later metastasize compared with those that do not. (D) Kaplan-Meier curve of disease 
free survival in patients with stage II disease. Patients were stratified into high or low expression groups based around mean stromal miR-
556 expression for the group as a whole. (E) Kaplan-Meier curve of disease free survival in patients with stage II disease. Patients were 
stratified into high or low expression groups based around mean stromal miR-21 and miR-556 and epithelial miR-106a expression for the 
group as a whole, and subdivided into groups expressing all candidate miRNAs at low levels, one or two candidate miRNAs at low levels 
or all miRNA candidates at high levels. (*p < 0.05).
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and regulating cellular adhesion and proliferative functions 
in a p53/p21 dependent manner [48]. Furthermore, miR-
215 suppression has been demonstrated in CRC, in a study 
which paradoxically linked declining miR-215 expression 
with improved overall survival [49]. However, as patterns 
of stromal miRNA expression are potentially made less 
distinct by the presence of extraneous epithelial tissue, 
this paradox may be explained by the use of bulk tumor 
specimens rather than LMD tissue.
In the present study, the only stromal miRNA 
upregulated more than 2X-fold in late stage (Duke’s C) 
vs. early stage (Duke’s A) CRC specimens, was miR-214. 
MiR-214 plays a key role in tissue fibrosis, a pathological 
process driven from the stroma [50, 51] and furthermore, 
upregulated stromal miR-214 expression was described 
previously in CRC in a study which compared LMD 
tumors with unpaired normal colonic tissue [21]. It is 
reassuring that several of our observations are mirrored in 
this complementary study by Nishida et al., namely that 
miR-214, miR-21 and members of the miR-17–92a cluster 
are strongly upregulated; and miR-215, miR-192 and miR-
194 downregulated in CRC stroma. However, having 
identified miRNA candidates deregulated in CRC stroma, 
the authors did not ascertain their prognostic significance, 
nor did they examine differentially expressed miRNAs in 
tumor vs. normal epithelium [21].
Here, the utility of deregulated miRNAs such as 
miR-21 in CRC stroma and miR-106a in CRC epithelium, 
were scrutinized in stage II disease, in a ‘real-world’ 
clinical scenario which presents significant prognostic and 
therapeutic challenges. In contrast, we found that stromal 
miR-214 and miR-215 were ubiquitously expressed in all 
stage II CRC specimens regardless of metastatic status 
at 5 years and hence they were not included in survival 
analysis. Nevertheless, miR-214 and miR-215 may still be 
biologically relevant in CRC and this raises an interesting 
point; that the same miRNAs deregulated in cancer are 
not necessarily deregulated during metastatic progression. 
Figure 6: Kaplan-Meier curve of overall survival in patients with stage II disease. Patients were stratified into high or low 
expression groups based around group mean stromal miR-21 expression (A) group mean epithelial miR-106a expression (B) and group 
mean stromal miR-556 expression (C) As elevated stromal miR-21 and epithelial miR-106a expression predicted significantly reduced 
overall survival they were included in combined analysis (D) whereas stromal miR-556 expression was excluded.
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Table 3: Demographic data for patients with stage II CRC stratified according to expression of 
stromal miR-21, stromal miR-556 and epithelial miR-106a in tumor
Characteristics All Low (n = 19) High/Low mix  
(n = 23)
All High (n = 8) p value
Age, years at diagnosis 
(mean+sd) 71.58 (13.52) 74.09 (10.17) 71.00 (10.57) 0.715
a
Gender (m:f) absolute 
numbers 13:6 18:5 7:1 0.537
b
Tumour site 0.730c
Right Colon 6 8 1
Left Colon 10 9 4
Rectum 3 5 3
Stoma 0 1 0
Surgical setting 0.285b
Elective 12 18 4
Emergency 7 5 4
Histopathological data
Maximum tumour diameter 
(mm) Mean (SD) 53.37 (21.94) 50.00 (25.91) 41.25 (9.10) 0.445
a
T stage 0.470c
T2 1 1 0
T3 14 16 4
T4 4 6 4
AJCC staging 7th ed 0.470c
Stage I 1 1 0
Stage IIA 14 16 4
Stage IIB 4 6 4
R0 resection margin 18 20 7 0.803b
Differentiation status 0.347c
Poor 2 1 1
Moderate-Poor 2 1 2
Moderate 10 9 2
Well-Moderate 5 12 3
Well 0 0 0
Extramural vascular 
invasion 2 1 2 0.248
b
Tumour perforation 1 2 0 0.662b
Adjuvant therapy
Neoadjuvant 
Chemotherapy 3 1 1 0.454
b
(Continued )
Oncotarget7274www.impactjournals.com/oncotarget
Crucially, this observation supports the view that molecular 
mechanisms underpinning the metastatic cascade are 
distinct from those which drive carcinogenesis [52].
To broaden and enrich our search for clinically 
relevant miRNAs, we adopted a miRnome-wide profiling 
approach to specifically compare miRNA expression in stage 
II CRC specimens with and without recurrence at 5 years. 
In this comparison of 20 patients (10 stage IIR vs.10 stage 
IINR) 95 consistently deregulated miRNAs were identified 
in stroma compared with 63 miRNAs in tumor epithelium.
Most cancer research is focused on tumor cells, 
but because stromal cells are less likely to acquire 
de-novo mutations, evade anti-cancer immunity, or 
develop drug resistance than malignant epithelial cells, 
the concept of stroma targeted therapy has become 
increasingly attractive [53, 54]. Another important 
theme in recent years is the development of therapies 
which target or exploit non-coding RNAs [30, 31, 34]. 
In this context, the characterization of miRNAs 
differentially expressed in metastatic vs. non-metastatic 
tumor groups may reveal opportunities to develop novel 
pharmacological interventions both in malignant tissue 
and the supportive tumor microenvironment.
MiRNAs such as miR-21 and miR-320 which are 
known to be active in the tumor microenvironment, have 
important regulatory roles within stromal cell such as 
fibroblasts, and in the malignant state impact on disease 
progression by modulating cellular secretory functions or 
facilitating other changes in cellular phenotype [15, 17, 20]. 
Other miRNAs are selectively sequestered into exosomes 
and actively exported from cells in a manner which 
is dependent both on gatekeeper proteins and specific 
miRNA sequence motifs. [55] Crucially, exosomal 
miRNA transfer from stromal cells to target cells also 
impacts significantly on disease progression in various 
tumor contexts [56, 57].
In the current study miR-556 was the most 
upregulated stromal miRNA identified in stage II-R CRC 
specimens. To establish whether stromal miR-556 has a 
significant biological role during the metastatic cascade 
will require further detailed in silico, functional and 
mechanistic studies. However, regardless of any putative 
biological function, deregulated stromal miR-556 may 
have a role as a biomarker of disease progression in CRC 
as the current study demonstrates an association between 
stromal miR-556 expression and decreased DFS stage II 
disease. In particular, when combined with stromal miR-
21 and epithelial miR-106a, stromal miR-556 contributed 
to a distinct molecular signature of disease recurrence: 
At 3 years following surgery with curative intent, 3/19 
(16%) patients expressing low levels of all three miRNAs 
had developed metastases compared with 10/23 (43%) 
patients expressing high levels of one or two miRNAs 
and 7/8 (88%) patients expressing high levels of all three 
miRNAs.
In summary, we have demonstrated that stromal 
and epithelial miRNA profiles may be used to identify 
patients at high risk of CRC recurrence and reduced OS. 
Our data supports the notion that miRNAs are important 
actors during the metastatic cascade, and that miRNA 
profiling may be a valuable aid to therapeutic decision 
making.
Furthermore, by demonstrating that miRNA 
profiles from fresh frozen CRC tissue correlate closely 
with FFPE tissue, a widely available clinical resource, 
we highlight the translational appeal of this research. 
However, in order to fully evaluate these findings, 
additional validation in a larger and independent cohort 
will be required.
MATERIALS AND METHODS
Clinical samples
Consecutive pairs of primary colonic tumor and 
adjacent non-tumorous colonic tissue were obtained during 
surgery at University Hospital Southampton as part of a 
prospective National Institute of Health Research study 
(UKCRN ID 6067). Although secreted miRNAs are present 
within the tumor microenvironment [58, 59] and their 
paracrine effects are not yet fully understood, [60] for the 
purpose of this study, macroscopically normal tissue > 5 cm 
from tumor margin was assumed to be non-malignant. 
This is consistent with traditional surgical practice which 
requires more than 5cm of oncological clearance in order to 
Characteristics All Low (n = 19) High/Low mix  
(n = 23)
All High (n = 8) p value
Neoadjuvant 
Radiotherapy 3 2 1 0.780
b
Adjuvant Chemotherapy 2 3 3 0.190b
Adjuvant Radiotherapy 2 0 1 0.252b
Mean follow up, years (s.d) 4.76 (1.74) 4.02 (2.49) 3.05 (2.11) 0.176a
a = One way ANOVA, b = Chi squared test, c = Kruskal-Wallace
Oncotarget7275www.impactjournals.com/oncotarget
ensure microscopic mesenteric lymph node deposits are not 
excluded from the resection specimen [61, 62].
Half of each specimen was frozen in liquid nitrogen 
and stored at −80°C, and half fixed in formalin and 
embedded in paraffin. From this archive, 5 early stage 
(Duke’s A) and 5 late stage (Duke’s C) specimens were 
selected at random to examine for array-based differential 
gene expression between normal and tumor tissue.
Subsequently, a further 50 consecutive and formalin 
fixed paraffin embedded (FFPE) CRC specimens were 
obtained from the study cohort. This cohort comprised 25 
patients with stage II disease who developed metastasis 
within 5 years and 25 carefully matched patients who 
remained metastasis free in that time (Table 1). Pathological 
verification of diagnosis and staging was in accordance with 
the Association of Coloproctology of Great Britain and 
Ireland guidelines on the management of CRC [63].
All specimens were stored in a designated UK 
Human Tissue Act approved tumor bank. Comprehensive 
demographic, clinical and pathological information was 
collated and hereditary tumors, mucinous tumors, and 
tumors with histologically identified necrosis excluded. 
All patients provided written informed consent and 
regional ethical approval was obtained.
Slide preparation, laser capture microdissection 
and RNA extraction
Frozen specimens were sectioned using a cryostat 
at 8–10 μm thickness onto membrane-mounted slides 
(Molecular Devices). FFPE specimens were sectioned 
using a microtome and subjected to deparaffinisation 
in Xylene for 1 minute. Tissue sections were then fixed 
in 75% ethanol for 30s and stained with Cresyl Violet 
for 1 min before undergoing a further dehydration step 
in 100% ethanol. Once air dried, LMD was performed 
using the Leica AS LMD microdissection platform (Leica 
Microsystems, UK) and cut tissue was collected directly 
into 50 μl of cell lysis buffer (Applied Biosystems). 
Approximately 1 × 106 μm2 was dissected from each slide. 
Malignant colonic epithelium and tumor associated stroma 
and normal colonic epithelium and normal stroma were 
each microdissected separately.
Total RNA extraction was conducted immediately 
using either the RNAqueous®-Micro Kit (Ambion) for 
fresh-frozen tissue or the RecoverAll™ kit (Ambion) for 
FFPE in accordance with the manufacturer’s instructions. 
RNA concentration and quality was determined using the 
Nanodrop™ 1000 spectrophotometer (Thermo Scientific) 
and a ratio of absorbance at 260 nm and 280 nm ≈ 2 was 
considered ‘pure’.
RT-PCR for cancer array plate with 
QuantimiRTM
The cancer array plate with QuantiMiRTM 
(Cambridge Biosciences) utilizes a reverse transcription 
(RT) step to convert miRNAs into quantifiable cDNAs 
which are then amplified for 95 different cancer-associated 
miRNAs and detected using SYBR Green fluorescent 
dye. This kit was used according to the manufacturer’s 
instructions. Briefly, 100 ng total RNA was dried down 
by vacuum centrifugation and resuspended in 5 μl of 
nuclease-free water. The RNA was modified by the 
addition of a polyA tail to which an oligo dT adaptor was 
annealed. The RT reagents from the kit (5 × buffer, dNTP 
mix, DTT, RNase-free dH2O and reverse transcriptase 
enzyme) were added to the modified RNA and the RT 
step was performed at 42°C for 60 min then inactivated 
at 95°C for 10 min. cDNA was mixed with 2 × Power 
SYBR® master mix (Applied Biosystems), RNase-free 
dH2O and a universal reverse primer (complementary to 
the adaptor sequence on each cDNA molecule) and the 
mix was aliquoted into 96 wells of an optical microplate. 
95 forward primers (10 μmoles) specific to a selection of 
cancer-related miRNAs and one for the U6 small RNA 
control were added to separate wells on the plate. cDNA 
was amplified using the ABI-HT7500 qPCR instrument 
(Applied Biosystems) and the following cycling 
parameters (50°C for 2 min; 95°C for 10 min and 40 
cycles of 95°C for 15 sec and 60°C for 1 min). Expression 
levels, normalized with the global median value for the 
whole plate, were calculated using the ΔΔCT method 
and expressed relative to one of the specimens that was 
assigned the value 1.
MiRnome wide gene expression analysis
Microarray data acquisition and presentation was 
conducted in accordance with MIAME guidelines [64]. 
The biomarker potential of data acquired was assessed in 
accordance with REMARK guidelines [65].
Briefly, 100 ng total RNA was dried down by 
vacuum centrifugation and resuspended in 3 μl of 
nuclease-free water. Hy3™ fluorescence labelled RNA 
was prepared using the miRCURY LNA™ microRNA 
Array Hi-Power labelling kit (Exiqon) in accordance 
with the manufacturer’s instructions. For each labelling 
reaction, 3 μl total RNA was combined with 1 μl ‘Spike-in’ 
miRNA control, 0.5 μl CIP buffer and 0.5 μl CIP enzyme. 
The ‘Spike-in’ control contains 52 different synthetic 
unlabeled miRNAs corresponding to capture probes on the 
miRCURY LNA™ 7th generation microRNA microarrays 
from Exiqon and various concentrations. This reaction mix 
was incubated for 30 minutes at 37°C using a PCR cycler 
with heated lid. After 30 minutes, the enzyme reaction 
was stopped and the RNA denatured by incubation at 
90°C followed by snap cooling on ice for 5–15 minutes. 
Subsequently this 5 μl reaction mix was combined with 
1.5 μl Hy3™ fluorescent label, 3 μl Hi-Power labelling 
buffer, 2 μl DMSO and 1 μl of Hi-Power labelling enzyme 
and incubated in darkness at 16°C. To stop the Hi-Power 
labelling reaction after 2 hours the sample was heated to 
65°C for 15 minutes and then placed immediately on ice.
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Labelled RNA was subsequently hybridized 
to miRCURY LNA™ 7th generation microRNA 
microarrays using a commercially available kit from 
Exiqon. Hybridization was conducted for 16 hours at 
56°C following which, array slides were washed, dried by 
cerntifugation and scanned using a GenePix 4000B scanner 
(Molecular Devices) to detect Hy3™ at a wavelength of 
532 nm. Image analysis was performed using GenePixPro 
3.0.5 software, which permitted a miRbase v19 updated 
gal file (www.exiqon.com/Gal-downloads) containing a 
mapping grid to be superimposed and accurately aligned 
onto the array image in TIFF format.
Whole miRnome microarray data was processed 
by subtracting background signals from the foreground 
signals for each feature. Any features which had a non-
zero flag or a background subtracted signal < 0.5 was set to 
‘missing.’ Expression signals were then log2 transformed 
and quartile normalized. After normalisation, any features 
targeting non-human miRNAs were removed. Data was 
sorted according to fold change (> 2) and p-value (< 0.05).
The nature of the platform meant that each miRNA 
probe was represented 4 times. For each miRNA, the 
mean value from 4 data points was used and an expression 
ratio calculated between LMD stroma/epithelium from 
recurrence and non-recurrence groups.
Quantitative expression analysis using Taqman® 
qRT-PCR
For each qPCR assay 2.5 ng total RNA from LMD 
samples (0.5 ng/μl) was converted into cDNA using 
a miRNA-specific RT step. The TaqMan® MicroRNA 
Reverse Transcription kit (Applied Biosystems) was used 
according to the manufacturer’s instructions in conjunction 
with a miRNA-specific looped reverse primer. The RT 
reagents (10 × RT buffer, dNTPs, RNase Inhibitor, RNase-
free dH2O and MultiScribe
TM Reverse transcriptase (50 U/
μl)) were combined with total RNA and the appropriate 
RT primer was added to the tube. The following RT 
reaction conditions were applied; 16°C for 30 min; 42°C 
for 30 min, 85°C for 5 min and 4°C hold. For the 20 μl 
PCR reaction; 10 μl Taqman 2 × Universal PCR Master 
Mix (Applied Biosystems) was added to 1.33 μl of cDNA, 
7.67 μl RNase-free dH2O and 1 μl of Taqman MicroRNA 
Assay primer and probe mix. Taqman Primer and probe 
mixes supplied by Applied Biosystems, used in the study 
include U6B (4427975; 001093), hsa-miR-224 (4427975; 
000599), hsa-miR-214 (4427975; 000517), hsa-miR-215 
(4427975; 000518), hsa-miR-21 (4427975; 00397), hsa-
miR-19a (4427975; 002424), hsa-miR-192 (4427975; 
000491), hsa-miR-194 (4427975; 000493), hsa-miR-200a 
(4427975; 001011), hsa-miR-556 (4427975; 002344) and 
hsa-miR-106a (4427975; 000578).
Reactions were performed in triplicate in 96 well 
plates covered with optical adhesive seal. The ABI-
HT7500 qPCR instrument (Applied Biosystems) was used 
with the following cycling parameters: 95°C for 10 min 
and 40 cycles of 95°C for 15 sec and 60°C for 60 sec. 
Expression levels, normalized with U6 qPCR assay were 
calculated using the ΔΔCT method and expressed relative 
to one of the specimens that was assigned the value 1.
Statistical analysis
Differences between paired tumor and normal tissue 
samples were expressed as fold-change, using the mean 
expression value from the normal group as the reference and 
the Wilcoxon signed rank test for statistical significance. 
Differences between Duke’s A and Duke’s C tumor groups 
were expressed as fold-change using the mean value from 
the Duke’s A group as a reference and the Mann-Whitney 
U test for statistical significance. Differences between 
recurrence and non-recurrence groups in stage II disease 
were expressed as fold-change using the mean value from 
the non-recurrence group as a reference and an unpaired 
student’s t-test for statistical significance. The threshold 
level of significance was set at 0.05 for all tests.
Correlation analysis between FFPE and fresh-
frozen tissue, using QuantimiR™ miRNA array data was 
conducted by normalizing CT values using the “norm.
rankinvariant” method from the R Bioconductor package 
“HTqPCR”: http://www.bioconductor.org/packages/
release/bioc/html/HTqPCR.html
Data is presented in a scatterplot format. Pearson 
correlation coefficients are reported.
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